Literature DB >> 6109223

Alpha- and beta-adrenoceptor blockade does not affect ventilation during exercise in man.

R Fagard, T Reybrouck, P Lijnen, A Amery, E Moerman, A De Schaepdryver.   

Abstract

Alpha- and beta-adrenoceptor blockade does not affect ventilation during exercise in man. Med. Sci. Sports Exercise, Vol. 12, No. 5, pp. 375-379, 1980. Combined alpha- and beta-adrenoceptor blockade was used to study the role of the exercise induced stimulation of the adrenergic system on exercise hyperpnea. Twelve subjects performed an uninterrupted graded exercise test until exhaustion, before and during treatment with the alpha- and beta-adrenoceptor blocker labetalol. In the control study, plasma noradrenaline rose on the average 4.3 times during maximal exercise and plasma adrenaline 2.7 times, with similar data during labetalol. Labetalol did not affect oxygen uptake, carbon dioxide output, respiratory exchange ratio, pulmonary ventilation, nor the ventilatory equivalents for O2 and for CO2 at rest recumbent, at rest sitting, and during submaximal and maximal exercise, nor did it affect the anaerobic threshold. These findings do not substantiate a role for the adrenergic system in exercise hyperpnea in the conditions of the present study.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6109223

Source DB:  PubMed          Journal:  Med Sci Sports Exerc        ISSN: 0195-9131            Impact factor:   5.411


  3 in total

Review 1.  Exercise performance and beta-blockade.

Authors:  P A Tesch
Journal:  Sports Med       Date:  1985 Nov-Dec       Impact factor: 11.136

2.  Ventilatory transients during exercise: peripheral or central control?

Authors:  R Favier; D Desplanches; J Frutoso; M Grandmontagne; R Flandrois
Journal:  Pflugers Arch       Date:  1983-03       Impact factor: 3.657

3.  Effects of beta-adrenoceptor blockade on exercise performance and respiratory response in healthy, physically untrained humans.

Authors:  B Violante; G Buccheri; V Brusasco
Journal:  Br J Clin Pharmacol       Date:  1984-12       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.